ANL
Adlai Nortye Ltd. Sponsored ADR · NASDAQ
- Sector Commercial Services
- Industry Miscellaneous Commercial Services
- Website adlainortye.com
- Employees(FY) 130
- ISIN US00704R1095
Performance
-5.66%
1W
+23.11%
1M
+57.77%
3M
+48.74%
6M
+44.61%
YTD
-13.33%
1Y
Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.
Technical Analysis of ANL 2024-05-10
Overview:
In the last 5 trading days, ANL stock has shown mixed signals across various technical indicators. The trend indicators suggest a slight bearish sentiment, with the moving averages and MACD showing a downward trend. Momentum indicators also indicate a weakening momentum, while volatility indicators show a narrowing Bollinger Bands rang...
Recent News & Updates
- 2024-04-24 21:40
- 2024-03-29 08:40
- 2024-03-29 06:00
- 2024-03-28 18:00
- 2023-11-16 18:30
- 2023-10-22 20:12
- 2023-10-03 00:05
- 2023-09-28 14:46
Page 1 of 1
previousnext